CardioVascular BioTherapeutics Co-Founder Presents Seminar on Potential New Heart Disease Treatment.LAS VEGAS Las Vegas (läs vā`gəs), city (1990 pop. 258,295), seat of Clark co., S Nev.; inc. 1911. It is the largest city in Nevada and the center of one of the fastest-growing urban areas in the United States. -- CardioVascular BioTherapeutics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CVBT CVBT Cardiovascular Biotherapeutics, Inc CVBT Central Virginia Battlefields Trust (Fredericksburg, VA Civil War history organization) ) today announced that Co-Founder and Chief Clinical Officer Dr. Thomas Stegmann will present the keynote address at a free seminar sponsored by the Regenerative Medicine Organization, a Las Vegas based non-profit organization. Dr. Stegmann's presentation "New Hope for Patients Suffering from Cardiovascular Disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease " will discuss the potential benefits of Cardio Vascu-Grow(TM), the active ingredient in CVBT's drug candidate currently in a U.S. Food and Drug Administration authorized clinical trial that represents a potential new treatment for heart disease. The seminar will occur both at 6:00 p.m. and 8:00 p.m. on Tuesday, September 19, 2006, at the New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Hilton, 1335 Avenue of the Americas, 3rd Floor, New York, New York. Cardio Vascu-Grow(TM) contains a protein that is being evaluated for its potential to increase the blood supply to damaged organs and tissues and potential to stimulate the growth of new blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. . The premise of this new therapy is once blood perfusion Blood perfusion A physiological term that refers to the process of nutritive delivery of arterial blood to a capillary bed in the biological tissue. Mentioned in: Interstitial Microwave Thermal Therapy is established through the growth of new blood vessels, patients with cardiovascular disease may experience improved quality of life. CVBT recently announced the completion of enrollment in a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I in no-option heart patients -- coronary heart patients who are not eligible for traditional interventional therapies such as bypass or stenting procedures. "Cardiovascular disease is the biggest health threat Americans face today, killing nearly 2,500 people each day. Lower cost, more effective treatments are needed," said Dr. Stegmann. "Cardio Vascu-Grow(TM) represents a potential breakthrough treatment and offers a chance to change the effect that heart disease has on our society. Attendees to this seminar will come away with an understanding of how Cardio Vascu-Grow(TM) may offer a potential new option in the treatment of cardiovascular disease." "Use of Cardio Vascu-Grow(TM) may be a part of a regenerative treatment that could enhance the body's natural ability to regenerate tissues and organs," said John Laub, Executive Director of Regenerative Medicine Organization. "Dr. Stegmann is a visionary in the field of regenerative medicine and his presentation at the Regenerative Medicine Organization's seminar will provide insight into this new potential alternative for addressing cardiovascular disease." There is no cost to attend this seminar. Please call 877-291-8700 or go to www.regenmd.org to reserve a seat. About CardioVascular BioTherapeutics CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting two FDA-authorized clinical trials: one in coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. in no-option heart patients, and one in impaired wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. A foreign clinical trial relating to chronic back pain believed to be caused by impaired or blocked lumbar arteries has also been initiated. Cardio Vascu-Grow is a trademark of CardioVascular BioTherapeutics, Inc. This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, results of future clinical and pre-clinical trials, differences in patient outcomes, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion